Amyloid plaques have long been the suspected cause of cognitive decline experienced by Alzheimer's patients. For two decades drug companies have spent billions of dollars creating amyloid-targeting drugs. Yet, they've all failed. 

I worked with STAT Biotech reporter Damian Garde on this project. I think we did a pretty good job of getting a lot of dense info across while keeping the video accessible.
Boston, Mass.